Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.67 |
| ▸ | STAT3 | P40763 | 5/20 | 0.46 |
| ▸ | GIPR | P48546 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2663319 | 0.91 | GCGR (0.75) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2666459 | 0.89 | GCGR (0.64) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL9072847 | 0.88 | GCGR (0.67) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2653454 | 0.88 | GCGR (0.63) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2650541 | 0.87 | GCGR (0.60) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL4094162 | 0.87 | GCGR (0.62) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL4097486 | 0.86 | GCGR (0.64) | GCGRSTAT3GIPRSMN1; SMN2GLP1R | |
| SCHEMBL2655374 | 0.86 | GCGR (0.80) | GCGRGIPRGLP1R | |
| SCHEMBL13800141 | 0.85 | GCGR (0.65) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2662082 | 0.85 | GCGR (0.63) | GCGRSTAT3GIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | claimed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-6875762-B2 | Tetracyclic azepinoindole compounds | PFIZER (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | PHARMACIA AND UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | GCGR 693/4885STAT3 4221/4885GIPR 152/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885STAT3 1079/4885GIPR 4/4885 |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | GCGR 929/4885STAT3 4669/4885GIPR 242/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | GCGR 929/4885STAT3 4669/4885GIPR 242/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885STAT3 1079/4885GIPR 4/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885STAT3 1079/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.